Patent US4614730A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4614730A Expired / Lapsed US ⏱️ 0.0 years remaining

Stabilized insulin preparations and a process for preparation thereof

Assignee: Novo Nordisk AS
•
Filing: 1984-07-31
•
Granted: 1986-09-30
•
Expires: 2004-07-31
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Isulin solutions physically stabilized by presence of one or more phospholipids, preferably a lecithin. The phospholipid is present in concentration of 10-200 mu g/ml.

Inventors

  • 👤 Philip E. Hansen
  • 👤 Jens J. V. Brange
  • 👤 Svend Havelund

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-29 08:25
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/28; A61K47/00; A61K47/06; A61K47/24

Claims Analysis

Total Claims: 3
Claim 1
Independent Claim 187 words
A process for producing an insulin solution of pH within the range of about pH 6.5-8 stabilized against interface polymerization, stabilization being ascertainable by submitting the insulin solution to shaking and measuring the time before opalescence appears in the insulin solution; said stabilized insulin solution being adapted for parenteral administration by portable or implantable system for continuous infusion of insulin, which process comprises mixing insulin with a phospholipid in a phospholipid to insulin weight ratio of 1:5 to 1:10,000, the phosphlolipid formula being: ##STR2## wherein R' and R" are the same or different each being selected from the group consisting of hydrogen, higher alkylcarbonyl, alkenylcarbonyl, alkadienylcarbonyl, alkatrienylcarbonyl and alkatetraenylcarbonyl, with the proviso that both R' and R" are not hydrogen, and R'" is selected from the group consisting of 2-(trimethylammonio)ethyl, 2-aminoethyl, 2-carboxy-2-aminoethyl, 2,3-dihydroxpropyl and 2,3,4,5,6-pentahydroxycyclohexyl, in the presence of water, and optionally with a zinc salt, a preservative, an agent rendering the insulin solution isotonic, and a buffering agent so as to obtain a concentration of phospholipid of 10-200 μg/ml of stablilized insulin solution, the insulin in solution being essentially outside any liposomes formed by said phospholipid.
Claim 2
Dependent Claim 187 words
A process for producing an insulin solution of pH within the range of about pH 6.5-8 stabilized against interface polymerization, stabilization being ascertainable by submitting the insulin solution to shaking and measuring the time before opalescence appears in the insulin solution; said stabilized insulin solution being adapted for parenteral administration by portable or implantable system for continuous infusion of insulin, which process comprises mixing insulin with a phospholipid in a phospholipid to insulin weight ratio of 1:5 to 1:10,000, the phosphlolipid formula being: ##STR2## wherein R' and R" are the same or different each being selected from the group consisting of hydrogen, higher alkylcarbonyl, alkenylcarbonyl, alkadienylcarbonyl, alkatrienylcarbonyl and alkatetraenylcarbonyl, with the proviso that both R' and R" are not hydrogen, and R'" is selected from the group consisting of 2-(trimethylammonio)ethyl, 2-aminoethyl, 2-carboxy-2-aminoethyl, 2,3-dihydroxpropyl and 2,3,4,5,6-pentahydroxycyclohexyl, in the presence of water, and optionally with a zinc salt, a preservative, an agent rendering the insulin solution isotonic, and a buffering agent so as to obtain a concentration of phospholipid of 10-200 μg/ml of stablilized insulin solution, the insulin in solution being essentially outside any liposomes formed by said phospholipid.
Claim 3
Dependent Claim 35 words
The process of claim 1 further comprising preparing said phospholipid solution by adding the phospholipid to water then subjecting the resulting mixture to ultrasonic treatment, whereafter the phospholipid solution is added to the insulin solution.

References Cited (Backward Citations)

US4153689A Cited
US4164573A Cited
US4145410A Cited
DE2652636A1 Cited
US4224179A Cited
US4229360A Cited
US4229360B1 Cited
US4235871A Cited
US4377567A Cited
EP0032622A1 Cited
DE2952119A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1989-09-29 1990-03-31 1990-09-30 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1993-09-29 1994-03-31 1994-09-30 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1997-09-29 1998-03-31 1998-09-30 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag